Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Profusa develops injectable biosensor technology for continuous physiological monitoring, primarily targeting defense, healthcare, and research applications. The company's Lumee Oxygen Platform uses tissue-integrated sensors smaller than a grain of rice to measure oxygen, glucose, and other biomarkers continuously for months without external devices. With zero revenue, extreme negative cash flow, and a 99% stock decline, this is a pre-commercial biotech facing severe liquidity constraints and potential insolvency.
Profusa operates as a pre-revenue development-stage biotech funded through non-dilutive government grants (primarily defense applications for continuous physiological monitoring) and private equity. The business model depends on securing regulatory approval (FDA 510(k) or PMA) for its Lumee biosensor platform, then monetizing through direct sales to healthcare systems, licensing to pharmaceutical companies for clinical trials, or partnerships with continuous glucose monitoring competitors. The technology's competitive advantage lies in its tissue-integrated approach eliminating external wearables, but commercialization remains unproven. Current financials suggest the company has exhausted funding runway.
FDA regulatory milestones (510(k) clearance, IDE approval for pivotal trials, PMA submission)
Clinical trial data releases showing sensor accuracy, biocompatibility, and duration performance
Government contract awards or renewals (DARPA, BARDA funding announcements)
Strategic partnerships or licensing deals with established medtech/pharma companies
Financing events (equity raises, debt facilities, bankruptcy proceedings given current distress)
Competitive developments in continuous glucose monitoring (Abbott FreeStyle, Dexcom G7) affecting market positioning
FDA regulatory approval uncertainty - implantable biosensors face rigorous biocompatibility, accuracy, and long-term safety requirements with multi-year approval timelines
Reimbursement risk - payers may not cover novel continuous monitoring technology without robust clinical outcomes data demonstrating cost-effectiveness versus existing CGM devices
Competitive obsolescence - rapid advancement in non-invasive wearable sensors (optical, RF-based) could eliminate market need for implantable technology before commercialization
Established CGM leaders (Dexcom, Abbott) have massive installed bases, superior distribution, and continuous product iteration making market entry extremely difficult
Non-invasive monitoring technologies (smartwatches, optical sensors) advancing rapidly, potentially eliminating need for any implantable solution
Pharmaceutical companies developing internal continuous monitoring capabilities for clinical trials, reducing licensing opportunity
Imminent insolvency risk - current ratio of 0.18 indicates inability to meet short-term obligations without immediate capital infusion
Negative book value and extreme negative ROA (-957%) suggest complete equity value impairment
99% stock price decline signals market expectation of bankruptcy or massive dilution
Zero revenue with ongoing cash burn creates binary outcome: successful financing/partnership or liquidation within months
moderate - Pre-revenue biotech is insulated from consumer spending cycles but highly sensitive to risk capital availability. Economic downturns reduce venture funding, IPO markets, and strategic acquirer appetite. Government defense/healthcare budgets (primary historical funding source) show moderate cyclicality. If commercialized, continuous monitoring adoption would correlate with healthcare spending growth and employer/insurer coverage decisions.
High negative sensitivity. Rising rates compress biotech valuations through higher discount rates on distant cash flows and reduce venture capital deployment. Pre-revenue companies with negative cash flow face acute refinancing risk in high-rate environments. The company's distressed financial position (current ratio 0.18, negative book value) makes access to capital markets critical, and rate increases severely constrain funding options. Additionally, rising rates reduce strategic acquirer willingness to pay premiums for early-stage assets.
Critical. With negative operating cash flow, minimal current ratio (0.18), and apparent funding exhaustion, the company requires immediate access to capital markets or strategic financing. Credit market tightening or high-yield spread widening would effectively eliminate refinancing options, forcing bankruptcy or distressed sale. No revenue generation means zero internal cash generation to service obligations.
Distressed/special situations investors and biotech venture specialists only. The 99% decline, zero revenue, and balance sheet distress eliminate traditional growth or value investors. Current holders likely include venture funds with sunk costs, distressed debt buyers anticipating bankruptcy claims, or extreme risk-tolerant speculators betting on binary FDA approval or acquisition. Institutional quality investors would avoid given insolvency risk and lack of near-term catalysts.
extreme - Stock exhibits characteristics of distressed equity with binary outcomes (survival vs. bankruptcy). Historical 99% decline demonstrates catastrophic volatility. Any regulatory news, financing announcement, or partnership rumor would drive 50%+ single-day moves. Illiquidity likely exacerbates price swings. Beta calculation meaningless given distressed status - volatility driven by company-specific survival probability rather than market correlation.